Insmed Inc INSM
We take great care to ensure that the data presented and summarized in this overview for INSMED Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INSM
View all-
Vanguard Group Inc Valley Forge, PA18.2MShares$1.26 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY14.3MShares$984 Million0.02% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y913MShares$894 Million84.75% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD12.7MShares$876 Million0.1% of portfolio
-
Capital International Investors Los Angeles, CA7.12MShares$491 Million0.1% of portfolio
-
State Street Corp Boston, MA6.11MShares$421 Million0.02% of portfolio
-
Baker Bros. Advisors LP New York, NY5.01MShares$345 Million3.83% of portfolio
-
Geode Capital Management, LLC Boston, MA4.09MShares$282 Million0.02% of portfolio
-
Pictet Asset Management Sa Geneva 73, V83.7MShares$255 Million0.09% of portfolio
-
Jpmorgan Chase & CO New York, NY3.29MShares$227 Million0.02% of portfolio
Latest Institutional Activity in INSM
Top Purchases
Top Sells
About INSM
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insider Transactions at INSM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 15
2025
|
William Lewis Chair and CEO |
SELL
Open market or private sale
|
Indirect |
6,830
-0.95%
|
$478,100
$70.49 P/Share
|
|
Apr 15
2025
|
William Lewis Chair and CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
6,830
+2.76%
|
$68,300
$10.85 P/Share
|
|
Apr 01
2025
|
William Lewis Chair and CEO |
SELL
Open market or private sale
|
Indirect |
6,830
-0.72%
|
$498,590
$73.94 P/Share
|
|
Apr 01
2025
|
William Lewis Chair and CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
6,830
+2.76%
|
$68,300
$10.85 P/Share
|
|
Mar 17
2025
|
William Lewis Chair and CEO |
SELL
Open market or private sale
|
Indirect |
6,830
-0.95%
|
$519,080
$76.95 P/Share
|
|
Mar 17
2025
|
William Lewis Chair and CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
6,830
+2.76%
|
$68,300
$10.85 P/Share
|
|
Mar 17
2025
|
William Lewis Chair and CEO |
SELL
Open market or private sale
|
Direct |
18,750
-1.8%
|
$1,425,000
$76.86 P/Share
|
|
Mar 17
2025
|
William Lewis Chair and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,750
+5.04%
|
$412,500
$22.76 P/Share
|
|
Mar 03
2025
|
William Lewis Chair and CEO |
SELL
Open market or private sale
|
Indirect |
6,830
-0.57%
|
$532,740
$78.81 P/Share
|
|
Mar 03
2025
|
William Lewis Chair and CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
6,830
+2.76%
|
$68,300
$10.85 P/Share
|
|
Mar 03
2025
|
William Lewis Chair and CEO |
SELL
Open market or private sale
|
Direct |
18,750
-1.08%
|
$1,462,500
$78.59 P/Share
|
|
Mar 03
2025
|
William Lewis Chair and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,750
+5.04%
|
$412,500
$22.76 P/Share
|
|
Feb 25
2025
|
Melvin Md Sharoky Director |
BUY
Bona fide gift
|
Indirect |
1,443
+9.94%
|
-
|
|
Feb 25
2025
|
Melvin Md Sharoky Director |
SELL
Bona fide gift
|
Direct |
1,443
-0.48%
|
-
|
|
Feb 18
2025
|
Sara Bonstein Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
18,322
-6.72%
|
$1,465,760
$80.64 P/Share
|
|
Feb 18
2025
|
William Lewis Chair and CEO |
SELL
Open market or private sale
|
Indirect |
6,830
-0.95%
|
$546,400
$80.96 P/Share
|
|
Feb 18
2025
|
William Lewis Chair and CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
6,830
+2.76%
|
$68,300
$10.85 P/Share
|
|
Feb 18
2025
|
William Lewis Chair and CEO |
SELL
Open market or private sale
|
Direct |
18,750
-1.78%
|
$1,500,000
$80.9 P/Share
|
|
Feb 18
2025
|
William Lewis Chair and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,750
+5.04%
|
$412,500
$22.76 P/Share
|
|
Feb 12
2025
|
Sara Bonstein Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,019
-3.53%
|
$401,520
$80.0 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 782K shares |
|---|---|
| Exercise of conversion of derivative security | 1.16M shares |
| Bona fide gift | 11.4K shares |
| Open market or private sale | 1.7M shares |
|---|---|
| Payment of exercise price or tax liability | 730 shares |
| Bona fide gift | 11.4K shares |